ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Biosynthesis and Immunological Evaluation of a Dual-Antigen Nanoconjugate Vaccine Targeting Group A Streptococcus.Vaccines · 2026Article
- Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024.Infectious diseases and therapy · 2026Article
- Article
- Review
- Group A Streptococcus among American Indian Persons, White Mountain Apache Tribal Lands, United States, 2016-2019Emerging infectious diseases · 2025Article
- Characterization ofMicroorganisms · 2025Article
- Immunization with the M12-N, M12-C, and M12-N+C fusion peptides derived from the M12 protein elicited varying levels of protective immune responses against multiple serotypes of group AFrontiers in immunology · 2025Article
- The intricate pathogenicity of Group AVirulence · 2024Review
- Realising the potential of correlates of protection for vaccine development, licensure and use: short summary.NPJ vaccines · 2024Article
- [Research progress on the mechanism of -lactam resistance in group AZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Research opportunities for the primordial prevention of rheumatic fever and rheumatic heart disease-streptococcal vaccine development: a national heart, lung and blood institute workshop report.BMJ global health · 2023Review
- Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- A Strep A vaccine global demand and return on investment forecast to inform industry research and development prioritization.NPJ vaccines · 2023Article
- The Streptococcus pyogenes vaccine landscape.NPJ vaccines · 2023Review
- Harmonizing Surveillance Methodologies for Group A Streptococcal DiseasesOpen forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritize research and surveillance activities. We focus on 4 objectives-advocacy, regulatory oversight and licensure, policy and post-licensure evaluation, and post-licensure financing-and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an underrecognized global burden, and give specific examples pertinent to 8 clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.